Navirel (Vinorelbine)

Vinorelbine interferes with microtubule assembly by binding to tubulin, preventing polymerization. This halts cells in the M‑phase of mitosis, leading to programmed cell death of rapidly dividing cancer cells while sparing most normal, non‑dividing tissues.

The specific dose of Navirel is individualized based on the patient’s condition, body surface area, and treatment protocol. The prescribing oncologist determines the appropriate regimen and adjusts it according to response and tolerability.

Vinorelbine is classified as Pregnancy Category D, indicating evidence of fetal risk. It should not be used during pregnancy, and effective contraception is required for women of childbearing potential. Breastfeeding is not recommended while receiving treatment.

To request Navirel, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required), and import documentation.

Vinorelbine belongs to the Vinca alkaloid class, similar to vincristine and vinblastine. Compared with taxane agents such as paclitaxel, vinorelbine typically shows a different toxicity profile, with less neuropathy but higher rates of neutropenia. Choice of therapy depends on tumor type, prior treatment, and patient tolerance.

Navirel must be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. Prior to administration, the product should be inspected for particulate matter and prepared using aseptic technique by qualified healthcare personnel.

Navirel is given by intravenous infusion, usually over 6–10 minutes for a single dose. The infusion is performed in a clinical setting by trained staff, with appropriate monitoring of vital signs and readiness to manage any acute reactions.

The most critical risks include severe neutropenia with fever or infection, pulmonary toxicity such as interstitial pneumonitis, peripheral neuropathy, and rare anaphylactic reactions. Patients should be monitored closely for signs of infection, respiratory distress, or allergic symptoms, and treatment should be adjusted promptly if they occur.

Navirel is contraindicated in pregnant women, patients with known hypersensitivity to vinorelbine or other Vinca alkaloids, and those with severe bone‑marrow suppression. Caution is also advised for individuals with significant hepatic impairment or uncontrolled cardiac conditions.